Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Toxicology".

Deadline for manuscript submissions: closed (2 December 2019) | Viewed by 11391

Special Issue Editors

Dr. Carlo Gabriele Tocchetti

E-Mail
Guest Editor
Department of Translational Medical Sciences, Federico II University, Via Pansini 5, Edificio 2, 80131 Naples, NA, Italy
Interests: cardio-oncology; heart failure
Special Issues, Collections and Topics in MDPI journals
Assist. Prof. Pietro Ameri

E-Mail
Guest Editor
University of Genova, Italy
Interests: cardio-oncology; heart failure
Dr. Alessandra Ghigo

E-Mail Website
Guest Editor
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy
Interests: cardio-oncology; signaling in cancer and the heart

Special Issue Information

Dear Colleagues,

With the prolongation in life expectancy, a continuously ageing population is more prone to developing chronic diseases. The prevalence of cardiovascular and oncologic disorders is also increasing, and there is an unmet need for life-saving treatments. This Special Issue is calling for original articles and state-of-the-art reviews that address the mechanisms and the clinical scenarios linking cancer, cardiovascular disorders and conventional and novel oncological therapies, in order to update the readers of IJMS with the major advancements in this field. Basic and clinical research are upfront in dissecting the complex, bidirectional interactions between cancer and cardiovascular disorders that frequently lead to an increased risk of cardiotoxicity from antineoplastic drugs, and in the quest for novel therapeutic strategies to fight these problems.

Assoc. Prof. Carlo Gabriele Tocchetti
Assist. Prof. Pietro Ameri
Assist. Prof. Alessandra Ghigo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2724 KiB  
Article
Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs
by Michaela Adamcova, Veronika Skarkova, Jitka Seifertova and Emil Rudolf
Int. J. Mol. Sci. 2019, 20(11), 2638; https://doi.org/10.3390/ijms20112638 - 29 May 2019
Cited by 14 | Viewed by 4272
Abstract
Modern diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction involve cardiac troponins measurement. Still, the role of other markers of cardiotoxicity is still unclear. The present study was designed to investigate dynamics of response of human cardiomyocytes derived from induced pluripotent [...] Read more.
Modern diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction involve cardiac troponins measurement. Still, the role of other markers of cardiotoxicity is still unclear. The present study was designed to investigate dynamics of response of human cardiomyocytes derived from induced pluripotent stem cells (hiPCS-CMs) to doxorubicin with the special emphasis on their morphological changes in relation to expression and organization of troponins. The hiPCS-CMs were treated with doxorubicin concentrations (1 and 0.3 µM) for 48 h and followed for next up to 6 days. Exposure of hiPCS-CMs to 1 µM doxorubicininduced suppression of both cardiac troponin T (cTnT) and cardiac troponin I (cTnI) gene expression. Conversely, lower 0.3 µM doxorubicin concentration produced no significant changes in the expression of aforementioned genes. However, the intracellular topography, arrangement, and abundance of cardiac troponin proteins markedly changed after both doxorubicin concentrations. In particular, at 48 h of treatment, both cTnT and cTnI bundles started to reorganize, with some of them forming compacted shapes extending outwards and protruding outside the cells. At later intervals (72 h and onwards), the whole troponin network collapsed and became highly disorganized following, to some degree, overall changes in the cellular shape. Moreover, membrane permeability of cardiomyocytes was increased, and intracellular mitochondrial network rearranged and hypofunctional. Together, our results demonstrate complex effects of clinically relevant doxorubicin concentrations on hiPCS-CM cells including changes in cTnT and cTnI, but also in other cellular compartments contributing to the overall cytotoxicity of this class of cytostatics. Full article
(This article belongs to the Special Issue Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity)
►▼ Show Figures

Graphical abstract

16 pages, 7530 KiB  
Article
The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
by Jérôme Piquereau, Angèle Boet, Christine Péchoux, Fabrice Antigny, Mélanie Lambert, Mélanie Gressette, Benoît Ranchoux, Natalia Gambaryan, Valérie Domergue, Sharon Mumby, David Montani, Ian M. Adcock, Marc Humbert, Anne Garnier, Catherine Rucker-Martin and Frédéric Perros
Int. J. Mol. Sci. 2019, 20(7), 1527; https://doi.org/10.3390/ijms20071527 - 27 Mar 2019
Cited by 16 | Viewed by 3367
Abstract
The bromodomain and extra-terminal domain family inhibitors (BETi) are a promising new class of anticancer agents. Since numerous anticancer drugs have been correlated to cardiomyopathy, and since BETi can affect non-cancerous tissues, we aimed to investigate in healthy animals any ultrastructural BETi-induced alterations [...] Read more.
The bromodomain and extra-terminal domain family inhibitors (BETi) are a promising new class of anticancer agents. Since numerous anticancer drugs have been correlated to cardiomyopathy, and since BETi can affect non-cancerous tissues, we aimed to investigate in healthy animals any ultrastructural BETi-induced alterations of the heart as compared to skeletal muscle. Male Wistar rats were either treated during 3 weeks with I-BET-151 (2 or 10 mg/kg/day) (W3) or treated for 3 weeks then allowed to recover for another 3 weeks (W6) (3-weeks drug washout). Male C57Bl/6J mice were only treated during 5 days (50 mg/kg/day). We demonstrated the occurrence of ultrastructural alterations and progressive destruction of cardiomyocyte mitochondria after I-BET-151 exposure. Those mitochondrial alterations were cardiac muscle-specific, since the skeletal muscles of exposed animals were similar in ultrastructure presentation to the non-exposed animals. I-BET-151 decreased the respiration rate of heart mitochondria in a dose-dependent manner. At the higher dose, it also decreased mitochondrial mass, as evidenced by reduced right ventricular citrate synthase content. I-BET-151 reduced the right and left ventricular fractional shortening. The concomitant decrease in the velocity-time-integral in both the aorta and the pulmonary artery is also suggestive of an impaired heart function. The possible context-dependent cardiac side effects of these drugs have to be appreciated. Future studies should focus on the basic mechanisms of potential cardiovascular toxicities induced by BETi and strategies to minimize these unexpected complications. Full article
(This article belongs to the Special Issue Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

15 pages, 2203 KiB  
Review
Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection
by Martino Deidda, Valentina Mercurio, Alessandra Cuomo, Antonio Noto, Giuseppe Mercuro and Christian Cadeddu Dessalvi
Int. J. Mol. Sci. 2019, 20(19), 4928; https://doi.org/10.3390/ijms20194928 - 04 Oct 2019
Cited by 13 | Viewed by 3226
Abstract
Despite advances in supportive and protective therapy for myocardial function, cardiovascular diseases due to antineoplastic therapy—primarily cardiomyopathy associated with contractile dysfunction—remain a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators are searching for alternative strategies that [...] Read more.
Despite advances in supportive and protective therapy for myocardial function, cardiovascular diseases due to antineoplastic therapy—primarily cardiomyopathy associated with contractile dysfunction—remain a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators are searching for alternative strategies that can timely recognise cardiovascular damage—thus permitting a quick therapeutic approach—or prevent the development of the disease. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as tyrosine kinase inhibitors. In recent years, metabolomics has proved to be a practical tool to highlight fundamental changes in the metabolic state in several pathological conditions. In this article, we present the state-of-the-art technology with regard to the metabolic mechanisms underlying cardiotoxicity and cardioprotection. Full article
(This article belongs to the Special Issue Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop